Abeona Therapeutics Statistics
Share Statistics
Abeona Therapeutics has 43.47M shares outstanding. The number of shares has increased by 58.91% in one year.
| Shares Outstanding | 43.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.36M |
| Failed to Deliver (FTD) Shares | 23 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.64M, so 6.07% of the outstanding shares have been sold short.
| Short Interest | 2.64M |
| Short % of Shares Out | 6.07% |
| Short % of Float | 6.7% |
| Short Ratio (days to cover) | 10.79 |
Valuation Ratios
The PE ratio is -1.98 and the forward PE ratio is -4.12.
| PE Ratio | -1.98 |
| Forward PE | -4.12 |
| PS Ratio | 30.6 |
| Forward PS | 3.7 |
| PB Ratio | 7.22 |
| P/FCF Ratio | -2.87 |
| PEG Ratio | n/a |
Enterprise Valuation
Abeona Therapeutics Inc. has an Enterprise Value (EV) of 97.71M.
| EV / Earnings | -1.8 |
| EV / Sales | 27.92 |
| EV / EBITDA | -1.93 |
| EV / EBIT | -2.07 |
| EV / FCF | -2.62 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.15 |
| Quick Ratio | 4.15 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.31 |
| Cash Flow / Debt | -37.08 |
| Interest Coverage | -112.76 |
Financial Efficiency
Return on equity (ROE) is -3.65% and return on capital (ROIC) is -233.04%.
| Return on Equity (ROE) | -3.65% |
| Return on Assets (ROA) | -0.85% |
| Return on Capital (ROIC) | -233.04% |
| Revenue Per Employee | 41.67K |
| Profits Per Employee | -645.10K |
| Employee Count | 84 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 6.18% in the last 52 weeks. The beta is 1.5, so Abeona Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.5 |
| 52-Week Price Change | 6.18% |
| 50-Day Moving Average | 6.03 |
| 200-Day Moving Average | 5.57 |
| Relative Strength Index (RSI) | 56.72 |
| Average Volume (20 Days) | 253.36K |
Income Statement
In the last 12 months, Abeona Therapeutics had revenue of 3.50M and earned -54.19M in profits. Earnings per share was -2.53.
| Revenue | 3.50M |
| Gross Profit | 1.90M |
| Operating Income | -47.13M |
| Net Income | -54.19M |
| EBITDA | -50.57M |
| EBIT | -47.13M |
| Earnings Per Share (EPS) | -2.53 |
Balance Sheet
The company has 14.47M in cash and 5.40M in debt, giving a net cash position of 9.07M.
| Cash & Cash Equivalents | 14.47M |
| Total Debt | 5.40M |
| Net Cash | 9.07M |
| Retained Earnings | -749.52M |
| Total Assets | 120.59M |
| Working Capital | 94.23M |
Cash Flow
In the last 12 months, operating cash flow was -37.01M and capital expenditures -331.00K, giving a free cash flow of -37.34M.
| Operating Cash Flow | -37.01M |
| Capital Expenditures | -331.00K |
| Free Cash Flow | -37.34M |
| FCF Per Share | -1.75 |
Margins
Gross margin is 5.41K%, with operating and profit margins of -134.67K% and -154.82K%.
| Gross Margin | 5.41K% |
| Operating Margin | -134.67K% |
| Pretax Margin | -154.82K% |
| Profit Margin | -154.82K% |
| EBITDA Margin | -1.44K% |
| EBIT Margin | -1.35K% |
| FCF Margin | -1.07K% |
Dividends & Yields
ABEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -42.1% |
| FCF Yield | -14.28% |
Analyst Forecast
The average price target for ABEO is $18, which is 199.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 199.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jul 5, 2022. It was a backward split with a ratio of 1:25.
| Last Split Date | Jul 5, 2022 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -8.25 |
| Piotroski F-Score | 1 |